"In particular, some of the company’s study findings raised concerns due to insufficient and conflicting data –
including regarding genotoxicity and potentially harmful chemicals leaching from the company’s proprietary e-liquid pods
– that have not been adequately addressed and precluded the FDA from completing a full toxicological risk assessment of the products named in the company’s applications."